| Date | Title | Description |
| 13.11.2024 | Preclinical data for Cereno Scientific’s novel IP Receptor Agonist CS585 presented at ESC Congress 2024, now published in European Heart Journal | Preclinical data for Cereno Scientific’s novel IP Receptor Agonist CS585 presented at ESC Congress 2024, now published in European Heart Journal
Wed, Nov 13, 2024 08:00 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B),... |
| 11.11.2024 | Cereno Scientific secures minimum 250 MSEK loan financing to reach set milestones into 2026 | Cereno Scientific secures minimum 250 MSEK loan financing to reach set milestones into 2026
Mon, Nov 11, 2024 07:25 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech company developing innovative t... |
| 28.10.2024 | Cereno Scientific's Rising Star: A New Hope in Pulmonary Fibrosis Treatment | Cereno Scientific is making waves in the biotech world. The company recently announced a significant increase in its valuation, now pegged at 4.05 billion SEK, or 14.3 SEK per share. This boost comes on the heels of a pivotal decision: the ... |
| 25.10.2024 | Edison Investment Research increases valuation of Cereno Scientific to 4.05 BSEK or SEK 14.3 SEK/share after IPF selected as initial target indication for CS014 | Edison Investment Research increases valuation of Cereno Scientific to 4.05 BSEK or SEK 14.3 SEK/share after IPF selected as initial target indication for CS014
Fri, Oct 25, 2024 10:10 CET Report this content
Cereno Scientific (Nasdaq First... |
| 02.10.2024 | Edison Investment Research increases valuation of Cereno Scientific to 3.9 BSEK or SEK 13.9 SEK/share after positive topline data | Edison Investment Research increases valuation of Cereno Scientific to 3.9 BSEK or SEK 13.9 SEK/share after positive topline data
Wed, Oct 02, 2024 14:54 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a pioneering b... |
| 27.09.2024 | Cereno Scientific announces positive topline results of Phase IIa trial with lead candidate CS1 in Pulmonary Arterial Hypertension | Cereno Scientific announces positive topline results of Phase IIa trial with lead candidate CS1 in Pulmonary Arterial Hypertension
Fri, Sep 27, 2024 20:40 CET Report this content
Primary endpoint of safety and tolerability met successfully
... |
| 16.08.2024 | Cereno Scientific expands patent protection for PAH drug candidate CS1’s third patent family in Brazil | Cereno Scientific expands patent protection for PAH drug candidate CS1’s third patent family in Brazil
Fri, Aug 16, 2024 08:00 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovativ... |
| 20.06.2024 | Cereno Scientific releases BioStock interview with CEO Sten R. Sörensen regarding CS014 advancing to clinical Phase I | Cereno Scientific releases BioStock interview with CEO Sten R. Sörensen regarding CS014 advancing to clinical Phase I
Thu, Jun 20, 2024 07:50 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech devel... |
| 10.06.2024 | Cereno Scientific moves to new office space at GoCo Health Innovation City in Gothenburg | Cereno Scientific moves to new office space at GoCo Health Innovation City in Gothenburg
Mon, Jun 10, 2024 08:30 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative treatments f... |
| 03.06.2024 | Cereno Scientific initiates collaboration with the Pulmonary and Vascular Research Institute (PVRI) | Cereno Scientific initiates collaboration with the Pulmonary and Vascular Research Institute (PVRI)
Mon, Jun 03, 2024 08:30 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative t... |
| 30.05.2024 | Cereno Scientific to present preclinical data for drug candidate CS585, a novel IP receptor agonist, at the ESC Congress 2024 | Cereno Scientific to present preclinical data for drug candidate CS585, a novel IP receptor agonist, at the ESC Congress 2024
Thu, May 30, 2024 08:30 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biote... |
| 28.05.2024 | Cereno Scientific participating at BIO 2024, June 3-6, San Diego | Cereno Scientific participating at BIO 2024, June 3-6, San Diego
Tue, May 28, 2024 08:34 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative treatments for rare and common cardi... |
| 23.05.2024 | Cereno Scientific publishes the interim report for Q1 2024 ( January 1–March 31) | Cereno Scientific publishes the interim report for Q1 2024 ( January 1–March 31)
Thu, May 23, 2024 08:30 CET Report this content
The Board and Chief Executive Officer of Cereno Scientific AB here present the interim report for Q1 2024 ( Jan... |
| 17.05.2024 | Cereno Scientific presents at ABGSC Investor Days, May 23 | Cereno Scientific presents at ABGSC Investor Days, May 23
Fri, May 17, 2024 08:30 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative treatments for rare and common cardiovascul... |
| 15.05.2024 | Cereno Scientific to present preclinical data for drug candidate CS585 at the EHA 2024 Hybrid Congress | Cereno Scientific to present preclinical data for drug candidate CS585 at the EHA 2024 Hybrid Congress
Wed, May 15, 2024 09:06 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovativ... |
| 02.05.2024 | Cereno Scientific: Nomination committee appointed ahead of annual general meeting 2025 | Cereno Scientific: Nomination committee appointed ahead of annual general meeting 2025
Thu, May 02, 2024 08:30 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative treatments for... |
| 16.04.2024 | Report from Annual General Meeting 2024 of Cereno Scientific AB | Report from Annual General Meeting 2024 of Cereno Scientific AB
Tue, Apr 16, 2024 13:05 CET Report this content
Today, April 16, 2024. Cereno Scientific AB (publ) held Annual General Meeting at the MAQS Advokatbyrå’s premises at Östra Hamng... |
| 11.04.2024 | Cereno Scientific expands patent protection for epigenetic HDAC inhibitor CS1:s second patent family | Cereno Scientific expands patent protection for epigenetic HDAC inhibitor CS1:s second patent family
Thu, Apr 11, 2024 08:30 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative ... |
| 10.04.2024 | Cereno Scientific submits Clinical Trial Application (CTA) for first-in-human Phase I study with novel epigenetic HDACi drug candidate CS014 | Cereno Scientific submits Clinical Trial Application (CTA) for first-in-human Phase I study with novel epigenetic HDACi drug candidate CS014
Wed, Apr 10, 2024 08:30 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a p... |
| 09.04.2024 | Cereno Scientific announces extended patent protection in Europe for CS585 program | Cereno Scientific announces extended patent protection in Europe for CS585 program
Tue, Apr 09, 2024 08:30 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative treatments for rar... |
| 03.04.2024 | Cereno Scientific releases Insights Video Season 3 Episode 9 with Dr. Björn Dahlöf, CSO, Cereno Scientific | Cereno Scientific releases Insights Video Season 3 Episode 9 with Dr. Björn Dahlöf, CSO, Cereno Scientific
Wed, Apr 03, 2024 08:30 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innov... |
| 28.03.2024 | Cereno Scientific participates at the ISHLT 44th Annual meeting and Scientific sessions to expand network and meet with investigators for the Phase II Study in PAH | Cereno Scientific participates at the ISHLT 44th Annual meeting and Scientific sessions to expand network and meet with investigators for the Phase II Study in PAH
Thu, Mar 28, 2024 08:30 CET Report this content
Cereno Scientific (Nasdaq Fi... |
| 27.03.2024 | Cereno Scientific releases Insights Video Season 3 Episode 8 with Dr. Björn Dahlöf, CSO, Cereno Scientific | Cereno Scientific releases Insights Video Season 3 Episode 8 with Dr. Björn Dahlöf, CSO, Cereno Scientific
Wed, Mar 27, 2024 08:30 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innov... |
| 26.03.2024 | Cereno Scientific publishes Annual Report for 2023 | Cereno Scientific publishes Annual Report for 2023
Tue, Mar 26, 2024 08:30 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative treatments for common and rare cardiovascular dise... |
| 25.03.2024 | Cereno Scientific participates at the upcoming medical conference ACC.24 to further build presence in the Cardiology community | Cereno Scientific participates at the upcoming medical conference ACC.24 to further build presence in the Cardiology community
Mon, Mar 25, 2024 08:30 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biot... |
| 22.03.2024 | Cereno Scientific announces new patent issued in 25 European countries for Phase II drug candidate CS1 | Cereno Scientific announces new patent issued in 25 European countries for Phase II drug candidate CS1
Fri, Mar 22, 2024 08:30 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatment... |
| 21.03.2024 | Warrants of series TO3 were exercised to approximately 99.6 percent and Cereno Scientific receives approximately SEK 76.7 million | Warrants of series TO3 were exercised to approximately 99.6 percent and Cereno Scientific receives approximately SEK 76.7 million
Thu, Mar 21, 2024 08:30 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PA... |
| 21.03.2024 | Cereno Scientific announces that a study protocol synopsis for the FDA approved Expanded Access Program for CS1 in PAH has been published on ClinicalTrials.gov | Cereno Scientific announces that a study protocol synopsis for the FDA approved Expanded Access Program for CS1 in PAH has been published on ClinicalTrials.gov
Thu, Mar 21, 2024 15:08 CET Report this content
Cereno Scientific (Nasdaq First ... |
| 19.03.2024 | Cereno Scientific announces new patent issued in Mexico for Phase II drug candidate CS1 | Cereno Scientific announces new patent issued in Mexico for Phase II drug candidate CS1
Tue, Mar 19, 2024 08:30 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common an... |
| 14.03.2024 | NOTICE TO ATTEND THE ANNUAL GENERAL MEETING OFCERENO Scientific AB (PUBL) | NOTICE TO ATTEND THE ANNUAL GENERAL MEETING OFCERENO Scientific AB (PUBL)
Thu, Mar 14, 2024 15:45 CET Report this content
The shareholders of Cereno Scientific AB (publ), company registration no. 556890-4071 (the “Company”), are hereby give... |
| 14.03.2024 | Last day of trading with warrants of series TO3 in Cereno Scientific is today, March 14, 2024 | Last day of trading with warrants of series TO3 in Cereno Scientific is today, March 14, 2024
Thu, Mar 14, 2024 08:30 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE U... |
| 14.03.2024 | The Nomination Committee’s proposed resolution to the Annual General Meeting on 16 April 2024 | The Nomination Committee’s proposed resolution to the Annual General Meeting on 16 April 2024
Thu, Mar 14, 2024 17:10 CET Report this content
The Nomination Committee in Cereno Scientific AB (publ) (the “Company”) proposes the following res... |
| 14.03.2024 | Don de Bethizy has been engaged as Senior Advisor to the Executive Management and Board of Directors of Cereno Scientific | Don de Bethizy has been engaged as Senior Advisor to the Executive Management and Board of Directors of Cereno Scientific
Thu, Mar 14, 2024 17:29 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a company developing i... |
| 14.03.2024 | Cereno Scientific's nomination committee proposes Dr. Gunnar Olsson and CEO Sten R. Sörensen as new members of the Board of Directors | Cereno Scientific's nomination committee proposes Dr. Gunnar Olsson and CEO Sten R. Sörensen as new members of the Board of Directors
Thu, Mar 14, 2024 17:19 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a company ... |
| 14.03.2024 | Cereno Scientific brings forward the publication of the Annual Report | Cereno Scientific brings forward the publication of the Annual Report
Thu, Mar 14, 2024 17:00 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascu... |
| 13.03.2024 | Cereno Scientific to attend BIO-Europe Spring in Barcelona, March 18–20, 2024 | Cereno Scientific to attend BIO-Europe Spring in Barcelona, March 18–20, 2024
Wed, Mar 13, 2024 08:30 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare car... |
| 12.03.2024 | BioStock has published an interview with Cereno Scientific’s CMO and Head of R&D, Dr. Rahul Agrawal | BioStock has published an interview with Cereno Scientific’s CMO and Head of R&D, Dr. Rahul Agrawal
Tue, Mar 12, 2024 08:52 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatmen... |
| 11.03.2024 | Cereno Scientific releases Insights Videos Season 3 Episode 7 with Dr. Raymond Benza, System Director of Pulmonary Hypertension, Mount Sinai Health System | Cereno Scientific releases Insights Videos Season 3 Episode 7 with Dr. Raymond Benza, System Director of Pulmonary Hypertension, Mount Sinai Health System
Mon, Mar 11, 2024 08:50 CET Report this content
Cereno Scientific (Nasdaq First North... |
| 06.03.2024 | Cereno Scientific publishes update and study protocol for the FDA approved Expanded Access Program for CS1 in PAH | Cereno Scientific publishes update and study protocol for the FDA approved Expanded Access Program for CS1 in PAH
Wed, Mar 06, 2024 08:30 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovativ... |
| 05.03.2024 | The exercise period for warrants of series TO3 in Cereno Scientific begins today | The exercise period for warrants of series TO3 in Cereno Scientific begins today
Tue, Mar 05, 2024 08:30 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES,... |
| 04.03.2024 | The exercise price for the warrants of series TO3 in Cereno Scientific has been determined to SEK 1.60 per share of series B | The exercise price for the warrants of series TO3 in Cereno Scientific has been determined to SEK 1.60 per share of series B
Mon, Mar 04, 2024 08:30 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, D... |
| 29.02.2024 | Cereno Scientific reports one new patient enrolled, one additional patient randomized, and one additional patient completed in the Phase II Study of CS1 in PAH | Cereno Scientific reports one new patient enrolled, one additional patient randomized, and one additional patient completed in the Phase II Study of CS1 in PAH
Thu, Feb 29, 2024 08:48 CET Report this content
Cereno Scientific (Nasdaq First ... |
| 28.02.2024 | Cereno Scientific to present at Life Science-dagen in Gothenburg on March 6, 2024 | Cereno Scientific to present at Life Science-dagen in Gothenburg on March 6, 2024
Wed, Feb 28, 2024 08:35 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare... |
| 27.02.2024 | Cereno Scientific releases Insights Videos Season 3 Episode 6 with Dr. Raymond Benza, System Director of Pulmonary Hypertension, Mount Sinai Health System | Cereno Scientific releases Insights Videos Season 3 Episode 6 with Dr. Raymond Benza, System Director of Pulmonary Hypertension, Mount Sinai Health System
Tue, Feb 27, 2024 08:17 CET Report this content
Cereno Scientific (Nasdaq First North... |
| 26.02.2024 | Edison Investment Research publishes Executive Interview with Rahul Agrawal, CMO and Head of R&D; and Björn Dahlöf, CSO, Cereno Scientific | Edison Investment Research publishes Executive Interview with Rahul Agrawal, CMO and Head of R&D; and Björn Dahlöf, CSO, Cereno Scientific
Mon, Feb 26, 2024 09:44 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a... |
| 23.02.2024 | Cereno Scientific releases Insights Videos Season 3 Episode 5 with Dr. Raymond Benza, System Director of Pulmonary Hypertension, Mount Sinai Health System | Cereno Scientific releases Insights Videos Season 3 Episode 5 with Dr. Raymond Benza, System Director of Pulmonary Hypertension, Mount Sinai Health System
Fri, Feb 23, 2024 08:51 CET Report this content
Cereno Scientific (Nasdaq First North... |
| 22.02.2024 | Edison Investment Research publishes Executive interview with Sten R. Sörensen, CEO, Cereno Scientific | Edison Investment Research publishes Executive interview with Sten R. Sörensen, CEO, Cereno Scientific
Thu, Feb 22, 2024 17:04 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatment... |
| 22.02.2024 | Edison Investment Research publishes first research on Cereno Scientific | Edison Investment Research publishes first research on Cereno Scientific
Thu, Feb 22, 2024 06:52 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiova... |
| 22.02.2024 | Cereno Scientific publishes year-end report for 2023 (1 January – 31 December) | Cereno Scientific publishes year-end report for 2023 (1 January – 31 December)
Thu, Feb 22, 2024 00:01 CET Report this content
The Board and Chief Executive Officer of Cereno Scientific AB here presents the year-end report for the year 2023... |
| 22.02.2024 | Cereno Scientific releases BioStock interview with CEO Sten R. Sörensen regarding recent announcements and the Year-End-report (Q4) | Cereno Scientific releases BioStock interview with CEO Sten R. Sörensen regarding recent announcements and the Year-End-report (Q4)
Thu, Feb 22, 2024 14:48 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a company de... |
| 21.02.2024 | Cereno Scientific reports progress of Expanded Access Program and announces timeline adjustment in the Phase II Study of CS1 in PAH | Cereno Scientific reports progress of Expanded Access Program and announces timeline adjustment in the Phase II Study of CS1 in PAH
Wed, Feb 21, 2024 17:55 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a company de... |
| 21.02.2024 | Edison Investment initiates coverage on Cereno Scientific | Edison Investment initiates coverage on Cereno Scientific
Wed, Feb 21, 2024 17:47 CET Report this content
It’s come to our attention that Edison has initiated coverage of Cereno with a valuation of SEK 2.32bn and a price range of SEK 9.9/sh... |
| 16.02.2024 | Cereno Scientific releases Insights Videos Season 3 Episode 1–4 with Sten R. Sörensen, CEO, Cereno Scientific | Cereno Scientific releases Insights Videos Season 3 Episode 1–4 with Sten R. Sörensen, CEO, Cereno Scientific
Fri, Feb 16, 2024 08:30 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative tr... |
| 13.02.2024 | Cereno Scientific announces new Executive Management Team | Cereno Scientific announces new Executive Management Team
Tue, Feb 13, 2024 13:26 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B) today announced that they have expanded the Executive Management Team to include the ne... |
| 13.02.2024 | Cereno Scientific appoints Dr. Rahul Agrawal as Chief Medical Officer and Head of R&D | Cereno Scientific appoints Dr. Rahul Agrawal as Chief Medical Officer and Head of R&D
Tue, Feb 13, 2024 13:09 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B) today announced that Dr. Rahul Agrawal has been appoint... |
| 06.02.2024 | Cereno Scientific releases Biostock interview with CEO Sten R. Sörensen on Expanded Access being approved by the FDA | Cereno Scientific releases Biostock interview with CEO Sten R. Sörensen on Expanded Access being approved by the FDA
Tue, Feb 06, 2024 09:32 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B) today announced that a video... |
| 02.02.2024 | Cereno Scientific, a clinical stage biotech with an innovative portfolio in common and rare CVD, appoints Julia Fransson as Director of Business Development | Cereno Scientific, a clinical stage biotech with an innovative portfolio in common and rare CVD, appoints Julia Fransson as Director of Business Development
Fri, Feb 02, 2024 15:52 CET Report this content
Cereno Scientific (Nasdaq First Nor... |
| 01.02.2024 | Cereno Scientific adds Project Director to strengthen business capabilities | Cereno Scientific adds Project Director to strengthen business capabilities
Thu, Feb 01, 2024 11:25 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardi... |
| 31.01.2024 | Cereno Scientific is granted Expanded Access by the FDA to drug candidate CS1 for rare disease pulmonary arterial hypertension | Cereno Scientific is granted Expanded Access by the FDA to drug candidate CS1 for rare disease pulmonary arterial hypertension
Wed, Jan 31, 2024 08:51 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a company develop... |
| 30.01.2024 | Cereno Scientific participates at the scientific conference PVRI 2024 Annual Congress to further build presence in the Pulmonary Hypertension community | Cereno Scientific participates at the scientific conference PVRI 2024 Annual Congress to further build presence in the Pulmonary Hypertension community
Tue, Jan 30, 2024 09:30 CET Report this content
Cereno Scientific (Nasdaq First North: C... |
| 25.01.2024 | Cereno Scientific releases Insights video season 2 episode 8 with Prof. Benza | Cereno Scientific releases Insights video season 2 episode 8 with Prof. Benza
Thu, Jan 25, 2024 09:20 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare car... |
| 22.01.2024 | Cereno Scientific announces that equity research company Edison initiates coverage of the company | Cereno Scientific announces that equity research company Edison initiates coverage of the company
Mon, Jan 22, 2024 08:45 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for... |
| 17.01.2024 | Cereno Scientific obtains first patent for drug candidate HDAC inhibitor CS014 in development for thrombosis prevention treatment | Cereno Scientific obtains first patent for drug candidate HDAC inhibitor CS014 in development for thrombosis prevention treatment
Wed, Jan 17, 2024 13:30 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a company deve... |
| 12.01.2024 | Cereno Scientific strengthens R&D with recruitment of Medical Director | Cereno Scientific strengthens R&D with recruitment of Medical Director
Fri, Jan 12, 2024 08:30 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardio... |
| 11.01.2024 | Cereno Scientific signs CordenPharma to manufacture CS1 for “compassionate use” supply and for next clinical trial of CS1 | Cereno Scientific signs CordenPharma to manufacture CS1 for “compassionate use” supply and for next clinical trial of CS1
Thu, Jan 11, 2024 08:30 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a company developing i... |
| 05.01.2024 | Cereno Scientific’s innovative study design of the Phase II study of CS1 in PAH published in renowned journal Pulmonary Circulation | Cereno Scientific’s innovative study design of the Phase II study of CS1 in PAH published in renowned journal Pulmonary Circulation
Fri, Jan 05, 2024 10:40 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a company de... |
| 05.01.2024 | Cereno Scientific releases Insights video season 2 episode 7 with Prof. Benza | Cereno Scientific releases Insights video season 2 episode 7 with Prof. Benza
Fri, Jan 05, 2024 14:30 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare car... |
| 04.01.2024 | Cereno Scientific submits request to the FDA for “compassionate use” of CS1 for treatment of patients with rare disease Pulmonary Arterial Hypertension (PAH) | Cereno Scientific submits request to the FDA for “compassionate use” of CS1 for treatment of patients with rare disease Pulmonary Arterial Hypertension (PAH)
Thu, Jan 04, 2024 08:00 CET Report this content
Cereno Scientific (Nasdaq First No... |
| 21.12.2023 | Cereno Scientific confirms new clinic activated in the Phase II study of drug candidate CS1 in rare disease PAH | Cereno Scientific confirms new clinic activated in the Phase II study of drug candidate CS1 in rare disease PAH
Thu, Dec 21, 2023 08:45 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative ... |
| 19.12.2023 | Cereno Scientific engages Carnegie Investment Bank as new Certified Adviser | Cereno Scientific engages Carnegie Investment Bank as new Certified Adviser
Tue, Dec 19, 2023 16:55 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardi... |
| 15.12.2023 | Cereno Scientific’s innovative drug candidate CS585 featured as one of the future antiplatelet strategies in the top-tier Journal of Thrombosis and Haemostasis | Cereno Scientific’s innovative drug candidate CS585 featured as one of the future antiplatelet strategies in the top-tier Journal of Thrombosis and Haemostasis
Fri, Dec 15, 2023 09:31 CET Report this content
Cereno Scientific (Nasdaq First ... |
| 13.12.2023 | Cereno Scientific’s novel HDACi CS014 has potential to become an effective antithrombotic therapy in patients with a high risk of thrombotic events as presented at the ASH Meeting | Cereno Scientific’s novel HDACi CS014 has potential to become an effective antithrombotic therapy in patients with a high risk of thrombotic events as presented at the ASH Meeting
Wed, Dec 13, 2023 09:10 CET Report this content
Cereno Scien... |
| 12.12.2023 | Report from the extraordinary general meeting of Cereno Scientific AB (publ) | Report from the extraordinary general meeting of Cereno Scientific AB (publ)
Tue, Dec 12, 2023 15:00 CET Report this content
Today, December 12, 2023, Cereno Scientific AB (publ) held an extraordinary general meeting at MAQS Advokatbyrå's p... |
| 12.12.2023 | Cereno Scientific’s CS585 could represent the first viable option of an IP receptor agonist for primary inhibition of thrombosis with reduced risk of bleeding as presented at the ASH Meeting | Cereno Scientific’s CS585 could represent the first viable option of an IP receptor agonist for primary inhibition of thrombosis with reduced risk of bleeding as presented at the ASH Meeting
Tue, Dec 12, 2023 11:15 CET Report this content
C... |
| 07.12.2023 | Cereno Scientific releases Insights video season 2 episode 6 with Phil B. Adamson, Abbott | Cereno Scientific releases Insights video season 2 episode 6 with Phil B. Adamson, Abbott
Thu, Dec 07, 2023 11:00 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common ... |
| 04.12.2023 | Cereno Scientific to present preclinical data for drug candidates CS014 and CS585 at the 65th ASH Annual Meeting & Exposition 2023 | Cereno Scientific to present preclinical data for drug candidates CS014 and CS585 at the 65th ASH Annual Meeting & Exposition 2023
Mon, Dec 04, 2023 15:35 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a company... |
| 01.12.2023 | Cereno Scientific completes preclinical safety program for innovative drug candidate CS014 targeting thrombosis prevention and reaches a major preparatory milestone towards the Phase I study | Cereno Scientific completes preclinical safety program for innovative drug candidate CS014 targeting thrombosis prevention and reaches a major preparatory milestone towards the Phase I study
Fri, Dec 01, 2023 11:00 CET Report this content
C... |
| 28.11.2023 | Cereno Scientific obtains first patent in India for drug candidate CS1 through its third patent family | Cereno Scientific obtains first patent in India for drug candidate CS1 through its third patent family
Tue, Nov 28, 2023 15:50 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatment... |
| 24.11.2023 | Cereno Scientific reports acquired warrants within the framework of the incentive programs | Cereno Scientific reports acquired warrants within the framework of the incentive programs
Fri, Nov 24, 2023 11:55 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common... |
| 24.11.2023 | Notice to attend the extraordinary general meeting of Cereno Scientific AB (publ) | Notice to attend the extraordinary general meeting of Cereno Scientific AB (publ)
Fri, Nov 24, 2023 14:45 CET Report this content
The shareholders of Cereno Scientific AB (publ), reg. no. 556890-4071 (the “Company”), are hereby given notice... |
| 23.11.2023 | Cereno Scientific will participate in the Nordic Life Science Days (NLSDays) on November 29-30, 2023 | Cereno Scientific will participate in the Nordic Life Science Days (NLSDays) on November 29-30, 2023
Thu, Nov 23, 2023 15:00 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments ... |
| 22.11.2023 | Cereno Scientific participates in the Nordic-American Healthcare Conference 2023 (NAHC) in New York City | Cereno Scientific participates in the Nordic-American Healthcare Conference 2023 (NAHC) in New York City
Wed, Nov 22, 2023 15:30 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatme... |
| 17.11.2023 | Cereno Scientific reports significant progress and a timeline adjustment in the Phase II study of CS1 in rare disease PAH | Cereno Scientific reports significant progress and a timeline adjustment in the Phase II study of CS1 in rare disease PAH
Fri, Nov 17, 2023 07:59 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a company developing i... |
| 17.11.2023 | Cereno Scientific publishes the interim report for Q3 2023 (July 1 – September 30) | Cereno Scientific publishes the interim report for Q3 2023 (July 1 – September 30)
Fri, Nov 17, 2023 08:30 CET Report this content
The Board and Chief Executive Officer of Cereno Scientific AB here present the interim report for Q3 2023 (Ju... |
| 17.11.2023 | Cereno Scientific move to request “compassionate use” of CS1 for treatment of patients with rare disease PAH | Cereno Scientific move to request “compassionate use” of CS1 for treatment of patients with rare disease PAH
Fri, Nov 17, 2023 07:59 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative tre... |
| 17.11.2023 | Cereno Scientific secures loan of SEK 90 million, extending the company's financial runway into 2025 and strengthening partnership opportunities | Cereno Scientific secures loan of SEK 90 million, extending the company's financial runway into 2025 and strengthening partnership opportunities
Fri, Nov 17, 2023 07:59 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B),... |
| 08.11.2023 | Cereno Scientific’s drug candidate CS585 highlighted by top-tier medical journal Blood as a promising novel anti-thrombotic strategy without risk of bleeding | Cereno Scientific’s drug candidate CS585 highlighted by top-tier medical journal Blood as a promising novel anti-thrombotic strategy without risk of bleeding
Wed, Nov 08, 2023 09:01 CET Report this content
Cereno Scientific (Nasdaq First No... |
| 07.11.2023 | Report from the extraordinary general meeting of Cereno Scientific AB (publ) | Report from the extraordinary general meeting of Cereno Scientific AB (publ)
Tue, Nov 07, 2023 11:50 CET Report this content
Today, November 7, 2023, Cereno Scientific AB (publ) held an extraordinary general meeting at MAQS Advokatbyrå's pr... |
| 01.11.2023 | Cereno Scientific releases Insights video season 2 episode 5 with Phil B. Adamson, Abbott | Cereno Scientific releases Insights video season 2 episode 5 with Phil B. Adamson, Abbott
Wed, Nov 01, 2023 09:30 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common ... |
| 27.10.2023 | Cereno Scientific expands patent protection for drug candidate CS1 through its second patent family | Cereno Scientific expands patent protection for drug candidate CS1 through its second patent family
Fri, Oct 27, 2023 15:45 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments f... |
| 26.10.2023 | Cereno Scientific assists the Swedish Economic Crime Authority | Cereno Scientific assists the Swedish Economic Crime Authority
Thu, Oct 26, 2023 13:11 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular dis... |
| 19.10.2023 | Notice to attend the extraordinary general meeting of Cereno Scientific AB (publ) | Notice to attend the extraordinary general meeting of Cereno Scientific AB (publ)
Thu, Oct 19, 2023 11:55 CET Report this content
The shareholders of Cereno Scientific AB (publ), reg. no. 556890-4071 (the “Company”), are hereby given notice... |
| 19.10.2023 | Cereno Scientific’s board proposes new board member Jeppe Øvlesen | Cereno Scientific’s board proposes new board member Jeppe Øvlesen
Thu, Oct 19, 2023 12:00 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular ... |
| 13.10.2023 | Cereno Scientific reports positive results from the data quality control review initiative in the Phase II study of CS1 in rare disease pulmonary arterial hypertension (PAH) | Cereno Scientific reports positive results from the data quality control review initiative in the Phase II study of CS1 in rare disease pulmonary arterial hypertension (PAH)
Fri, Oct 13, 2023 22:55 CET Report this content
Cereno Scientific ... |
| 06.10.2023 | Cereno Scientific releases Insights video season 2 episode 4 with Phil B. Adamson, Abbott | Cereno Scientific releases Insights video season 2 episode 4 with Phil B. Adamson, Abbott
Fri, Oct 06, 2023 10:50 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common ... |
| 29.09.2023 | Cereno Scientific’s Board, management and scientific advisors have subscribed warrants within the framework of the incentive programs | Cereno Scientific’s Board, management and scientific advisors have subscribed warrants within the framework of the incentive programs
Fri, Sep 29, 2023 08:30 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a company ... |
| 27.09.2023 | Cereno Scientific releases Insights video season 2 episode 3 with Phil B. Adamson, Abbott | Cereno Scientific releases Insights video season 2 episode 3 with Phil B. Adamson, Abbott
Wed, Sep 27, 2023 16:51 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common ... |
| 26.09.2023 | Cereno Scientific releases Insights video season 2 episode 2 with Prof. Benza | Cereno Scientific releases Insights video season 2 episode 2 with Prof. Benza
Tue, Sep 26, 2023 15:05 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare car... |
| 22.09.2023 | Cereno Scientific releases Insights video season 2 episode 1 with Prof. Benza | Cereno Scientific releases Insights video season 2 episode 1 with Prof. Benza
Fri, Sep 22, 2023 09:50 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare car... |
| 21.09.2023 | Cereno Scientific launches season 2 of the Insights Video Series | Cereno Scientific launches season 2 of the Insights Video Series
Thu, Sep 21, 2023 15:10 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular d... |
